Analyst Ratings For NASDAQ:MDGL – Madrigal Pharmaceuticals (NASDAQ:MDGL)
Today, Roth Capital raised its price target on NASDAQ:MDGL – Madrigal Pharmaceuticals (NASDAQ:MDGL) to per share.
Some recent analyst ratings include
- 5/31/2018-Cowen Reiterated Rating of Buy.
- 5/31/2018-Oppenheimer Upgrade from a “Market Perform ➝ Outperform” rating to a “” rating.
- 5/31/2018-UBS Group Upgrade from a “Market Perform ➝ Outperform” rating to a “” rating.
- 5/31/2018-Goldman Sachs Group Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:MDGL – Madrigal Pharmaceuticals (NASDAQ:MDGL)
NASDAQ:MDGL – Madrigal Pharmaceuticals (NASDAQ:MDGL) has insider ownership of 56.70% and institutional ownership of 45.56%.
- On 8/23/2017 Richard S Levy, Director, bought 2,000 with an average share price of $16.12 per share and the total transaction amounting to $32,240.00.
- On 8/22/2017 Richard S Levy, Director, bought 3,550 with an average share price of $16.12 per share and the total transaction amounting to $57,226.00.
- On 8/21/2017 Richard S Levy, Director, bought 3,550 with an average share price of $15.88 per share and the total transaction amounting to $56,374.00.
- On 12/14/2015 Keith R Gollust, Director, sold 600,000 with an average share price of $0.35 per share and the total transaction amounting to $210,000.00.
- On 12/9/2015 Keith R Gollust, Director, sold 745,892 with an average share price of $0.38 per share and the total transaction amounting to $283,438.96.
- On 12/8/2015 Bruce Kovner, Director, sold 1,523,346 with an average share price of $0.37 per share and the total transaction amounting to $563,638.02.
- On 12/3/2015 Bruce Kovner, Director, sold 1,430,753 with an average share price of $0.43 per share and the total transaction amounting to $615,223.79.
Recent Trading Activity for NASDAQ:MDGL – Madrigal Pharmaceuticals (NASDAQ:MDGL)
Shares of NASDAQ:MDGL – Madrigal Pharmaceuticals closed the previous trading session at 254.48 down -11.13 4.19% with shares trading hands.